

**Acute Lymphoblastic  
Leukemia**

# Acute Lymphoblastic Leukemia

Proceedings of a Wyeth-Ayerst-UCLA Western Workshop on  
Acute Lymphoblastic Leukemia Held at  
Tapatio Springs, Texas,  
November 29-December 2, 1988

---

---

## Editors

**Robert Peter Gale**

Department of Medicine  
Division of Hematology and Oncology  
UCLA School of Medicine  
The Center for the Health Sciences  
Los Angeles, California

**Dieter Hoelzer**

Zentrum der Inneren Medizin  
Johann Wolfgang Goethe University  
Frankfurt, Federal Republic of Germany

---

**Wiley-Liss • New York**

Address all Inquiries to the Publisher  
Alan R. Liss, Inc., 41 East 11th Street, New York, NY 10003

Copyright © 1990 Alan R. Liss, Inc.

Printed in United States of America

Under the conditions stated below the owner of copyright for this book hereby grants permission to users to make photocopy reproductions of any part or all of its contents for personal or internal organizational use, or for personal or internal use of specific clients. This consent is given on the condition that the copier pay the stated per-copy fee through the Copyright Clearance Center, Incorporated, 27 Congress Street, Salem, MA 01970, as listed in the most current issue of "Permissions to Photocopy" (Publisher's Fee List, distributed by CCC, Inc.), for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

While the authors, editors, and publisher believe that drug selection and dosage and the specifications and usage of equipment and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they accept no legal responsibility for any errors or omissions, and make no warranty, express or implied, with respect to material contained herein. In view of ongoing research, equipment modifications, changes in governmental regulations and the constant flow of information relating to drug therapy, drug reactions and the use of equipment and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each drug, piece of equipment or device for, among other things, any changes in the instructions or indications of dosage or usage and for added warnings and precautions.

The publication of this volume was facilitated by the authors and editors who submitted the text in a form suitable for direct reproduction without subsequent editing or proofreading by the publisher.

#### Library of Congress Cataloging-in-Publication Data

UCLA Western Workshop--Acute Lymphoblastic Leukemia (1988 : Tapatio Springs, Tex.)

Acute lymphoblastic leukemia : proceedings of a UCLA Western Workshop--Acute Lymphoblastic Leukemia, held at Tapatio Springs, Texas, November 29-December 2, 1988 / editors, Robert Peter Gale, D. Hoelzer.

p. cm. -- (UCLA symposia on molecular and cellular biology : new ser., v. 108)

Includes bibliographical references.

ISBN 0-471-56719-1

1. Lymphoblastic leukemia--Congresses. I. Gale, Robert Peter. II. Hoelzer, D. (Dieter) III. Title. IV. Series.

[DNLM: 1. Leukemia, Lymphocytic, Acute--congresses. W3 U17N new ser. v. 108 / WH 250 U174 1988a]

RC280.L9U28 1988

616.99'419--dc20

DNLM/DLC

for Library of Congress

89-24885

CIP

## Contributors

**Michael D. Amylon**, Department of Pediatrics, Stanford University Medical Center, Stanford, CA 94305 [279]

**Janet W. Andersen**, Division of Biostatistics, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA 02115 [197]

**Michael Andreeff**, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [147, 231]

**Luciana Annino**, Section on Hematology, Department of Biopathology, University 'La Sapienza', 00161 Rome, Italy [205]

**Ralph B. Arlinghaus**, Department of Molecular Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030 [81]

**Diane Arthur**, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 [101]

**C. Aul**, Zentrum der Inneren Medizin, Johann Wolfgang Goethe University, Frankfurt D-6000, and Zentrum der Inneren Medizin, University of Duesseldorf, Duesseldorf D-4000, Federal Republic of Germany [221, 253]

**John M. Bennett**, University of Rochester Cancer Center, Strong Memorial Hospital, Rochester, NY 14642 [197]

**Ellin Berman**, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [231]

**Irwin D. Bernstein**, Department of Pediatric Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA 98104 [293]

**B. Bizzi**, Section on Hematology, Department of Biopathology, University 'La Sapienza' 00161 Rome, Italy [205]

**Clara D. Bloomfield**, Department of Medical Oncology, University of Minnesota, Minneapolis, MN 55455 [101]

The numbers in brackets are the opening page numbers of the contributors' articles.

**Karl G. Blume**, Department of Medicine, Stanford University Medical Center, Stanford, CA 94305 [279]

**G. Broccia**, Department of Medicine, 'A. Businco' Hospital, Cagliari, Italy [205]

**K. Bross**, Medizinische Universitätsklinik, Freiburg 7800, Federal Republic of Germany [221]

**Th. Büchner**, Medizinische Universitätsklinik, Muenster D-4400, and Zentrum der Inneren Medizin, Johann Wolfgang Goethe University, Frankfurt D-6000, Federal Republic of Germany [221, 253]

**F.W. Busch**, Medizinische Universitätsklinik, Tübingen 7400, Federal Republic of Germany [221]

**Anna Butturini**, Department of Pediatrics, Division of Hematology and Oncology, University of Parma, Parma 4300, Italy [299]

**Dario Campana**, Department of Immunology, Royal Free Hospital School of Medicine, London NW3 2QG, England [111]

**Martin L. Campbell**, Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 [81]

**Molly Carey**, Department of Medical Oncology, University of Minnesota, Minneapolis, MN 55455 [101]

**Peter A. Cassileth**, University of Pennsylvania Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 [197]

**Richard E. Champlin**, Department of Medicine, Division of Clinical Immunology, Roswell Park Memorial Cancer Institute, Buffalo, NY 14263 [157]

**Nelson J. Chao**, Department of Medicine, Stanford University Medical Center, Stanford, CA 94305 [279]

**Bayard Clarkson**, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [231]

**Isabel Cunningham**, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [231]

**Janet Cuttner**, Department of Hematology, Mount Sinai Hospital, New York, NY 10029 [101]

**Frederick R. Davey**, Department of Pathology, State University of New York, Health Science Center at Syracuse, Syracuse, NY 13210 [101]

**H. Dietrich**, Zentrum der Inneren Medizin, Johann Wolfgang Goethe University, Frankfurt D-6000, Federal Republic of Germany [221]

**Rose Ruth Ellison**, Department of Oncology, Columbia-Presbyterian Medical Center, New York, NY 10032 [101]

**Philip Fialkow**, Department of Medicine, University of Washington, Seattle, WA 98195 [293]

**D.M. Fiere**, Department of Hematology, Hôpital Edouard Herriot, Université Claude Bernard, 69437 Lyon, Cedex 03, France [285]

**G. Fioritoni**, Department of Hematology, Civile Hospital, Pescara, Italy [205]

**Kenneth A. Foon**, Department of Medicine, Division of Clinical Immunology, Roswell Park Memorial Cancer Institute, Buffalo, NY 14263 [157]

**Richard J. Ford, Jr.**, Department of Molecular and Anatomic Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 [55]

**Stephen J. Forman**, Department of Hematology, Bone Marrow Transplant Unit, City of Hope National Medical Center, Duarte, CA 91010 [279]

**M. Freund**, Medizinische Hochschule, Hannover 3000, Federal Republic of Germany [221]

**Wayne L. Furman**, Department of Hematology-Oncology, St. Jude Children's Research Hospital, and The University of Tennessee, College of Medicine, Memphis, TN 38105 [143]

**Robert Peter Gale**, Department of Medicine, Division of Hematology and Oncology, University of California School of Medicine, The Center for The Health Sciences, Los Angeles, CA 90024 [157, 299, 309]

**A. Ganser**, Zentrum der Inneren Medizin, Johann Wolfgang Goethe University, Frankfurt D-6000, Federal Republic of Germany [221]

**Paul S. Gaynon**, Department of Pediatric Hematology/Oncology, University of Wisconsin Medical Center, Madison, WI 53792 [147]

**Jeffrey Gaynor**, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [231]

**Timothy Gee**, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [231]

**F. Giona**, Section on Hematology, Department of Biopathology, University 'La Sapienza', 00161 Rome, Italy [205]

**C. Gisselbrecht**, Department of Hematology, Hôpital Saint Louis, 75475 Paris, Cedex 10, France [285]

**G. Götz**, II Medizinische, Universitätsklinik Eppendorf, Hamburg 2000, Federal Republic of Germany [221]

**Alois Gratwohl**, Division of Hematology, Department of Internal Medicine, Kantonsspital Basel, (University of Basel), CH-4031 Basel, Switzerland [271]

**M.F. Greaves**, Leukaemia Research Fund Centre, Institute of Cancer Research, London SW3 6JB, England [1]

**F. Griesinger**, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 [35]

**John Groffen**, Section of Molecular Genetics, Division of Medical Genetics, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [69]

**Gerard Grosveld**, Department of Cell Biology and Genetics, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands [xix, 15]

**Subhash Gulati**, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [231]

**Richard G. Hahn**, Mayo Clinic, Rochester, MN 55905 [197]

**Joseph Haimi**, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [147]

**Denman Hammond**, Chairman, Operations Office, Childrens Cancer Study Group, Pasadena, CA 91101 [147]

**G. Heil**, Medizinische Universitätsklinik, Ulm 7900, Federal Republic of Germany [221]

**H. Heimpel**, Zentrum der Inneren Medizin, Johann Wolfgang Goethe University, Frankfurt D-6000, Federal Republic of Germany [221]

**A. Heinecke**, Department of Biostatistics, University of Muenster, Muenster D-4400, Federal Republic of Germany [253]

**Nora Heisterkamp**, Section of Molecular Genetics, Division of Medical Genetics, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [69]

**Jon Hermans**, Department of Medical Statistics, University of Leiden, Leiden 2333 AA, The Netherlands [271]

**W. Hiddemann**, Medizinische Universitätsklinik, Muenster D-4400, and Zentrum der Inneren Medizin, Johann Wolfgang Goethe University, Frankfurt D-6000, Federal Republic of Germany [221, 253]

**H. Clark Hoagland**, Mayo Clinic, Rochester, MN 55905 [197]

**Dieter Hoelzer**, Zentrum der Inneren Medizin, Johann Wolfgang Goethe University, Frankfurt D-6000, Federal Republic of Germany [221, 309]

**George Janossy**, Department of Immunology, Royal Free Hospital School of Medicine, London NW3 2QG, England [111]

**Guido Jenster**, Section of Molecular Genetics, Division of Medical Genetics, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [69]

**W. Kaboth**, Krankenhaus Schwabing, München 8000, Federal Republic of Germany [221]

**David K. Kalwinsky**, Department of Hematology-Oncology, St. Jude Children's Research Hospital, and The University of Tennessee, College of Medicine, Memphis, TN 38105 [143]

**Sanford Kempin**, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [231]

**John H. Kersey**, Departments of Laboratory Medicine, Pathology, and Pediatrics, University of Minnesota, Minneapolis, MN 55455 [35]

**P. Koch**, Medizinische Universitätsklinik Münster 4400, Federal Republic of Germany [221]

**H. Kolb**, Medizinisches Klinik III des Klinikums Crobhadern, München 8000, Federal Republic of Germany [221]

**P.N. Konrad**, Department of Pediatrics, City of Hope National Medical Center, Duarte, CA 91010 [279]

**R. Küchler**, Allgemeines Krankenhaus St. Georg, Hamburg 2000, Federal Republic of Germany [221]

**Michelle Le Beau**, Department of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637 [101]

**Tucker W. LeBien**, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 [29]

**Wanjun Li**, Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 [81]

**A. Lindemann**, I Medizinische Klinik und Poliklinik, Marz 6500, Federal Republic of Germany [221]

**T. Lipp**, Krankenhaus Schwabing, München 8000, Federal Republic of Germany [221]

**V. Liso**, Department of Hematology, Policlinico, Bari, Italy [205]

**Claudia Little**, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [231]

**H. Löffler**, Medizinische Universitätsklinik und Poliklinik, Kiel D-2300, Federal Republic of Germany [221, 253]

**W. Ludwig**, Department of Hematology/Oncology, Klinikum Steglitz, University of West Berlin, Berlin D-1000, Federal Republic of Germany [253]

**Barbara Lunghofer**, Cancer and Leukemia Group B (CALGB), DATA Management, Frontier Science and Technology Research Foundation, Amherst, NY 14226 [101]

**Franco Mandelli**, Section on Hematology, Department of Biopathology, University 'La Sapienza', 00161 Rome, Italy [205]

**M. Martelli**, Medical Clinic I, Policlinico 'Monteluce', Perugia, Italy [205]

**Paul J. Martin**, Department of Medicine, University of Washington, Seattle, WA 98195 [293]



**G. Maschmeyer**, Evangelisches Krankenhaus Essen-Werden, Essen D-4300, and Zentrum der Inneren Medizin, Johann Wolfgang Goethe University, Frankfurt D-6000, Federal Republic of Germany [221, 253]

**J. Maupas**, Department of Hematology, Hôpital Edouard Herriot, Université Claude Bernard, 69437 Lyon, Cedex 03, France [285]

**Joseph J. Mazza**, Department of Oncology, Marshfield Clinic, Marshfield, WI 54449 [197]

**Shashikant R. Mehta**, Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 [55]

**D. Messerer**, Biometrisches Zentrum für Therapiestudien München 8000, Federal Republic of Germany [221]

**M. Metternich**, Medizinische Universitätsklinik, Köln 5000, Federal Republic of Germany [221]

**Paul Meyers**, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [147]

**Rosie Mick**, Department of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637 [101]

**Mark Minden**, Department of Medicine and Bioresearch, Ontario Cancer Institute, Toronto, Ontario M4X 1K9, Canada [45]

**Christine Morris**, Section of Molecular Genetics, Division of Medical Genetics, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [69]

**M.R. Nowrousian**, Universitätsklinik Tumorforschung, Essen D-4300, and Zentrum der Inneren Medizin, Johann Wolfgang Goethe University, Frankfurt D-6000, Federal Republic of Germany [221, 253]

**Michael J. O'Connell**, Mayo Clinic, Rochester, MN 55905 [197]

**Grace Peng**, Department of Medical Oncology, University of Minnesota, Minneapolis, MN 55455 [101]

**A. Peta**, Department of Hematology, 'A. Pugliese' Hospital, Cantanzaro, Italy [205]

**H. Pralle**, Medizinische Universitätsklinik, Giessen 6300, Federal Republic of Germany [221]

**Ching-Hon Pui**, Department of Hematology-Oncology, St. Jude Children's Research Hospital, and The University of Tennessee, College of Medicine, Memphis, TN 38105 [91, 143]

**Susana C. Raimondi**, Departments of Pathology and Laboratory Medicine, St. Jude Children's Research Hospital, Memphis, TN 38105 [91]

**Arlene Redner**, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [147]

**L. Refegotti**, Department of Hematology, St. Giovanni Hospital, Turin, Italy [205]

**Gaston K. Rivera**, Department of Hematology-Oncology, St. Jude Children's Research Hospital, and The University of Tennessee, College of Medicine, Memphis, TN 38105 [91, 143]

**B. Rotoli**, Department of Hematology, Nuovo Policlinico, Napoli, Italy [205]

**Victor M. Santana**, Department of Hematology-Oncology, St. Jude Children's Research Hospital, and The University of Tennessee, College of Medicine, Memphis, TN 38105 [143]

**Gerard S. Schaison**, Department of Pediatric Hematology, Saint-Louis Hospital, 75010 Paris, France [265]

**Charles A. Schiffer**, Division of Hematologic Malignancies, University of Maryland Cancer Center, Division of Hematology and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201 [101, 129]

**Gerhard M. Schmidt**, Department of Hematology, Bone Marrow Transplant Unit, City of Hope National Medical Center, Duarte, CA 91010 [279]

**Jack Singer**, Department of Medicine, University of Washington, and the Veterans Administration Medical Center, Seattle, WA 98195 [293]

**Robert E. Sobol**, Department of Immunology, University of California San Diego Cancer Center, San Diego, CA 92103 [101]

**Laurel Steinherz**, Department of Pediatric Cardiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [147]

**Peter G. Steinherz**, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [147]

**Ramana Tantravahi**, Cytogenetics Laboratory, Dana-Farber Cancer Institute, Boston, MA 02115 [101]

**Joanne ten Hoeve**, Section of Molecular Genetics, Division of Medical Genetics, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [69]

**Joseph Testa**, Department of Cytogenetics, University of Maryland Cancer Center, Baltimore, MD 21201 [101]

**E. Thiel**, Klinikum Steglitz der Universität, Berlin 1000, Federal Republic of Germany [221]

**Douglas C. Tormey**, University of Wisconsin Clinical Cancer Center, Madison, WI 53792 [197]

**M.L. Vegna**, Section on Hematology, Department of Biopathology, University 'La Sapienza', 00161 Rome, Italy [205]

**A. Weiss**, III Medizinisches Klinik der Stadt, Mannheim 6800, Federal Republic of Germany [221]

**F.C. Wendt**, Evangelisches Krankenhaus, Essen-Werden 4300, Federal Republic of Germany [221]

**Dorothy L. Williams**, Departments of Pathology and Laboratory Medicine, St. Jude Children's Research Hospital, Memphis, TN 38105 [91]

**F. Witz**, Department of Hematology, Hôpital de Brabois, 54511 Vandoeuvre les Nancy, France [285]

**Doris Wurster-Hill**, Department of Pathology, Dartmouth Medical School, Hanover, NH 03756 [101]

**Ferry E. Zwaan**, Department of Hematology, Bone Marrow Transplant Unit, University Medical Center Leiden, Leiden 2333 AA, The Netherlands [271]

## André Hermans: In Memoriam

The Wyeth-Ayerst Laboratories-UCLA Workshop on **Acute Lymphoblastic Leukemia**, held in San Antonio, Texas, November 29-December 2, 1988, has been dedicated to our colleague André Hermans. For this generous initiative I am most grateful to the organizers Drs. Robert Peter Gale and Dieter Hoelzer.

After finishing Medical School in Amsterdam in 1984, André Hermans started his scientific training in the department of Cell Biology and Genetics at the Erasmus University, Rotterdam. He worked on the molecular charac-




André Hermans

terization of the Philadelphia translocation in Philadelphia-positive acute lymphoblastic leukemia. His major contribution to this field was the discovery of an alternative BCR-ABL gene fusion in this type of leukemia.

Since he understood both clinical and scientific problems, his future interest was to bridge the gap between the clinic and science, a task for which he was well qualified. Arrangements to reach his ideal had been made, his practical work had been finished, and he was writing up his thesis.

On November 9, 1988, André Hermans decided not to live any longer. Although we will never understand his reasoning and feelings, we will remember him as a bright, stimulating colleague and friend. His sudden death is a great loss for all who knew him—in particular for his wife Anne-Pauline and his family and friends, but also for his colleagues and the scientific community as a whole.

Gerard Grosveld



## Contents

<b>Contributors</b> .....	xi
<b>André Herimans: In Memoriam</b>	
Gerard Grosveld .....	xix
<b>I. BIOLOGY</b>	
<b>Etiology of Childhood Acute Lymphoblastic Leukemia: A Soluble Problem?</b>	
M.F. Greaves .....	1
<b>Philadelphia Positive Leukemia: Activation of the ABL Oncogene is Only the First Step in Understanding the Leukemic Process</b>	
Gerard Grosveld .....	15
<b>Some Thoughts on Normal and Leukemic Human B Cell Precursors</b>	
Tucker W. LeBien .....	29
<b>New Concepts in the Understanding of Target Cells in Acute Lymphoblastic Leukemia: ALL as a Heterogeneous Disease of Lymphoid Precursors and Multipotent Progenitors</b>	
F. Grisinger and John H. Kersey .....	35
<b>The Alpha and Delta Chains of the T-Cell Antigen Receptor Gene in Acute Lymphoblastic Leukemia</b>	
Mark Minden .....	45
<b>Human B Cell Growth Factors: Current Status and Future Prospects</b>	
Richard J. Ford, Jr. and Shashikant R. Mehta .....	55
<b>Children With Philadelphia Chromosome Positive ALL</b>	
Nora Heisterkamp, Joanne ten Hoeve, Guido Jenster, Christine Morris, and John Groffen .....	69
<b>Cytoplasmic Complexes Containing <i>bcr</i> Proteins: Insertion of an Activated <i>bcr-abl</i> Protein Kinase in Leukemic Cells</b>	
Ralph B. Arlinghaus, Wanjun Li, and Martin L. Campbell .....	81
<b>II. CLINICAL STUDIES</b>	
<b>Evolving Chromosome Patterns and New Cytogenetic Concepts in Childhood Acute Lymphoblastic Leukemia</b>	
Dorothy L. Williams, Susana C. Raimondi, Ching-Hon Pui, and Gaston K. Rivera .....	91

<b>Prognostic Significance of the Philadelphia Chromosome in Adult Acute Lymphoblastic Leukemia</b>	
C.D. Bloomfield, D. Wurster-Hill, G. Peng, M. Le Beau, R. Tantravahi, J. Testa, F.R. Davey, R.R. Ellison, J. Cuttner, C. Schiffer, R.E. Sobol, B. Lunghofer, M. Carey, R. Mick, and D. Arthur .....	101
<b>Critical Analysis of Detecting Minimal Residual Leukemia</b>	
Dario Campana and George Janossy .....	111
<b>Hybrid Leukemias</b>	
Charles A. Schiffer .....	129
<b>III. CHEMOTHERAPY</b>	
<b>High-Risk Groups Among Children With Acute Lymphocytic Leukemia</b>	
Gaston K. Rivera, Victor M. Santana, Ching-Hon Pui, Wayne L. Furman, and David K. Kalwinsky .....	143
<b>Improved Survival of Children With High-Risk Acute Lymphoblastic Leukemia: Report From the Childrens Cancer Study Group and the Memorial Sloan-Kettering "New York" Protocol</b>	
Peter G. Steinherz, Paul S. Gaynon, Joseph Haimi, Paul Meyers, Arlene Redner, Laurel Steinherz, Michael Andreeff, and Denman Hammond .....	147
<b>Therapy of Acute Lymphoblastic Leukemia</b>	
Kenneth A. Foon, Richard E. Champlin, and Robert Peter Gale .....	157
<b>High-Dose Cytarabine Therapy in Adult Acute Lymphocytic Leukemia</b>	
Peter A. Cassileth, Janet W. Andersen, H. Clark Hoagland, Joseph J. Mazza, John M. Bennett, Richard G. Hahn, Douglas C. Tormey, and Michael J. O'Connell .....	197
<b>Gimena ALL 0183: A Multicentric Study on Adult Acute Lymphoblastic Leukemia in Italy</b>	
F. Mandelli, L. Annino, F. Giona, M.L. Vegna, B. Bizzi, G. Broccia, G. Fioritoni, V. Liso, M. Martelli, A. Peta, L. Resegotti, and B. Rotoli ..	205
<b>Intensified Chemotherapy and Mediastinal Irradiation in Adult T-Cell Acute Lymphoblastic Leukemia</b>	
D. Hoelzer, E. Thiel, H. Löffler, T. Büchner, M. Freund, A. Ganser, G. Heil, W. Hiddemann, G. Maschmeyer, C. Aul, F.C. Wendt, K. Bross, H. Pralle, R. Küchler, H. Dietrich, M. Metternich, A. Lindemann, T. Lipp, W. Kaboth, M.R. Nowrousian, P. Koch, F.W. Busch, H. Heimpel, G. Götz, A. Weiss, H. Kolb, and D. Messerer .....	221
<b>Clinical Trials in Adults With Acute Lymphoblastic Leukemia at Memorial Sloan-Kettering Cancer Center</b>	
Bayard Clarkson, Jeffrey Gaynor, Claudia Little, Ellin Berman, Sanford Kempin, Michael Andreeff, Subhash Gulati, Isabel Cunningham, and Timothy Gee .....	231
<b>Adult AML: How Can Chemotherapy be Improved?</b>	
T.H. Büchner, W. Hiddemann, G. Maschmeyer, W. Ludwig, H. Löffler, M. Nowrousian, C. Aul, and A. Heinecke .....	253
<b>Treatment of High-Risk Acute Lymphoblastic Leukemia</b>	
Gerard S. Schaison .....	265

#### IV. TRANSPLANTATION

<b>Bone Marrow Transplantation for ALL in Europe</b>	
Alois Gratwohl, Jon Hermans, and Ferry Zwaan .....	271
<b>*Bone Marrow Transplantation for Acute Lymphoblastic Leukemia</b>	
K.G. Blume, G.M. Schmidt, N.J. Chao, M.D. Amylon, P.N. Konrad, and S.J. Forman .....	279
<b>Comparison of Chemotherapy, Autologous and Allogeneic Transplantation as Post Induction Regimen in Adult Acute Lymphoblastic Leukemia: A Preliminary Multicentric Study</b>	
D. Fiere, C. Gisselbrecht, F. Witz, and J. Maupas .....	285
<b>Marrow Purging: Are Our Concepts Correct?</b>	
Irwin D. Bernstein, Paul J. Martin, Jack Singer, and Philip Fialkow .....	293

#### V. CONCLUSION

<b>Controversies in the Biology and Therapy of Acute Lymphoblastic Leukemia</b>	
Robert Peter Gale and Anna Butturini .....	299
<b>Acute Lymphoblastic Leukemia: Current Controversies, Future Directions</b>	
Robert Peter Gale and Dieter Hoelzer .....	309
<b>Index</b> .....	323



ETIOLOGY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA:  
A SOLUBLE PROBLEM?<sup>1</sup>

M F Greaves

Leukaemia Research Fund Centre,  
Institute of Cancer Research,  
Fulham Road, London SW3 6JB

Acute lymphoblastic leukemia (ALL) is the major subtype of pediatric cancer in developed countries (1) and is remarkable clinically in that a substantial proportion of cases are curable with relatively modest doses of chemotherapy and prophylactic CNS radiation (2); the basis for this success is unknown.

ALL is a biologically diverse disease and can be divided into broad subgroups according to immunological and karyotypic criteria (Table 1). These subtypes have varying clinical responses and correspond approximately to developmental stages of B and T cell precursor populations (3). It is important to appreciate that the correspondence between leukemic and normal cells accommodates the fact that the former have asynchronous phenotypes and that the dominant leukemic cell phenotype does not necessarily identify the target cell for the disease which could reside at a less differentiated developmental level (cf CML). This latter issue is important from both a therapeutic and etiologic viewpoint. Table 2 summarises what are the likely target cells for childhood ALL. These are either multipotential stem cells or lymphoid (T or B) stem cells.

The distinctive and diverse chromosomal abnormalities associated with these subtypes (Table 1; see also paper by Williams et al) are likely to be important components of the etiological mechanisms involved. Their diversity and cell type specificity presumably reflect in some way the selective advantage that certain genes or the proteins they encode can confer at particular stages of differentiation (3).

<sup>1</sup>This work was supported by the Leukaemia Research Fund of Great Britain.